A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

This is an early-phase safety study testing a new drug called ZG006 in people with small cell lung cancer whose disease has stopped responding to standard treatments. The goal is to find the right dose and check safety. **You may be eligible if...** - You have been diagnosed with small cell lung cancer that has not responded to, or you could not tolerate, standard treatments - Your tumor tests positive for a protein called DLL3 - Your life expectancy is at least 3 months - You are generally well enough to be up and about most of the day (ECOG score 0 or 1) - You are willing to use contraception during treatment and for 6 months after **You may NOT be eligible if...** - You received chemotherapy or other cancer drugs within the past 4 weeks - You have been on high-dose steroids (more than 10 mg prednisone daily) within the past 2 weeks - You received a vaccine (COVID, flu, etc.) within the past 4 weeks - You have had a severe, life-threatening reaction to a previous immunotherapy - You have an active infection such as hepatitis B/C, HIV, or tuberculosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.